Multidrug-resistant Enterobacteriaceae including metallo-β-lactamase producers are predominant pathogens of healthcare-associated infections in an Indian teaching hospital

Indian Journal of Medical Microbiology

Volumn 29, Issue 1, 2011, Pages 22-27

  Sarma, J ^a   Bhattacharya, P ^b   Kalita, D ^b   Rajbangshi, M ^b  

^a NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^b GAUHATI MEDICAL COLLEGE   (India)

Author keywords

extended spectrum lactamase; healthcare associated infections; metallo lactamase; meticillin resistant S. aureus; surgical site infections

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LINEZOLID; METALLO BETA LACTAMASE; METRONIDAZOLE; MONOBACTAM; OFLOXACIN; ORNIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TINIDAZOLE;

ADULT; ARTICLE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CANDIDA; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; HEALTH ASSOCIATED INFECTION; HEALTH CARE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR ACCESS SITE INFECTION; PHLEBITIS; POSTOPERATIVE INFECTION; PREVALENCE; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; TEACHING HOSPITAL; UNITED KINGDOM; VASCULAR ACCESS;

EID: 79951999342     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.76519     Document Type: Article

References (24)

1. Sarma JB, Ahmed GU. Infection control with limited resources: Why and how to make it possible? Indian J Med Microbiol 2010;28:11-6.
2. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64:i29-36.
3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
4. Surgical Site Infection, NICE Guideline 2008. National Institute for Health and Clinical Excellence Clinical Guideline 74. Available from: http://www.nice.org.uk/nicemedia/pdf/CG74NICEGuideline.pdf. [cited in 2008].
5. Sarma JB, Ahmed GU. Characterisation of methicillin resistant S. aureus strains and risk factors for acquisition in a teaching hospital in northeast India. Indian J Med Microbiol 2010;28:127-9.
6. Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical Site Infection (SSI) Rates in the United States, 1992-1998: The National Nosocomial Infections Surveillance System Basic SSI Risk Index. Clin Infect Dis 2001;33:S69-77.
7. Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index: National Nosocomial Infections Surveillance System. Am J Med 1991;91:152S-7S.
8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. (Pubitemid 351763841)
9. New carbapenemase, NDM-1, linked to India and Pakistan. ARMRL News, Health Protection Agency; vol. 23, 2009. p. 1-2.
10. Madeo M. The role of air ventilation and air sampling in reducing the incidence of surgical wound infection rates. Br J Theatre Nurs 1996;6:29-32.
11. Dharan S, Pittet D. Environmental controls in operating theatres. J Hosp Infect 2002;51:79-84. (Pubitemid 37554816)
12. Whyte W, Hambraeus A, Laurell G, Hoborn J. The relative importance of the routes and sources of wound contamination during general surgery. J Hosp Infect 1992;22:41-54.
13. Humphreys H, Taylor EW. Operating theatre ventilation standards and the risk of postoperative infection. J Hosp Infect 2002;50:85-90. (Pubitemid 37554885)
14. Ayliffe GA. Role of the environment of the operating suite in surgical wound infection. Rev Infect Dis 1991;13:S800-4.
15. Drake CT, Goldman E, Nichols RL, Piatriszka K, Nyhus LM. Environmental air and airborne infections. Ann Surg 1977;185:219-23.
16. Anderson DJ, Kaye KS, Classen D, Arias KM, Podgorny K, Burstin H, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29:S51-61.
17. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002;51:1-26. Available from://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5110a1.htm.
18. Sarma JB, Ahmed GU. Prevalence and risk factors for colonisation with extended spectrum β-lactamase producing enterobacteriacae vis-à-vis usage of antimicrobials. Indian J Med Microbiol 2010;28:217-20.
19. Cantón R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006;9:466-75.
20. Antibiotic Prophylaxis in Surgery. Scottish Intercollegiate Guidelines Network, Guideline No. 104, ISBN 978 1 905813 34 6, July 2008. Available from: http://www.sign.ac.uk/guidelines/fulltext/104/index.html.
21. Walsh TR, Toleman MA, Jones RN. Comment on: Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2007;59:799-800; author reply 800-1.
22. Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 2008;14:159-65. (Pubitemid 350269196)
23. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006;9:466-75.
24. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74. (Pubitemid 47072053)